John D. Halpern 13D and 13G filings for BROOKLYN IMMUNO THERAPEUTICS L:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-31 07:05 am Purchase | 2023-12-31 | 13G | Ernexa Therapeutics Inc. ERNA | John D. Halpern | 36,726 9.990% | 6,574 (+21.80%) | Filing |
| 2023-01-31 4:05 pm Purchase | 2023-01-31 | 13G | Ernexa Therapeutics Inc. ERNA | John D. Halpern | 30,152 8.800% | 74 (+0.25%) | Filing |
| 2022-12-05 5:20 pm Sale | 2022-12-02 | 13G | Ernexa Therapeutics Inc. ERNA | John D. Halpern | 30,078 8.800% | -286,405 (-90.50%) | Filing |
| 2021-05-24 1:03 pm Purchase | 2021-03-25 | 13G | Ernexa Therapeutics Inc. ERNA | John D. Halpern | 15,824 11.400% | 15,824 (New Position) | Filing |